This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information  are necessary to accomplish a better ...

Multiple myeloma (MM) is a clonal B-lymphocyte neoplasm of terminally differentiated plasma cells. Imaging modalities which allow the recognition of the effects of myeloma cells on the skeletal system have been utilized for a long time. Herein, we represent a patient with generalized osteoporosis and hypercalcemia, who was referred for parathyroid scan, in whom the widespread bone marrow techne...

the coexistence of two malignancies is rarely seen. a little association between hematologic malignancies especially multiple myeloma and renal cell carcinoma has been reported in the recent past. several case series revealed a bidirectional association between these two malignancies which may be due to the common risk factors, similar cytokine growth requirements and clinical presentation. her...

A 79-year-old female came to skin clinic with an ulcer, 15×20 cm, on her left shin. The laboratory report and both the skin and bone marrow biopsies reports, showed pyoderma gangrenosum associated with multiple myeloma. The patient was referred to hematology clinic for treatment. Multiple myeloma has rarely been associated with pyoderma gangrenosum. Multiple myeloma should be investigated...

normal 0 false false false en-us x-none fa background : the aim of the study was to assess the effects of combination of bortezomib moderate dose and continuous oral low dose melphalan and thalidomide and dexamethasone (bmtd regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (mm). methods : twenty four patients with advanced mm were enrolled to receive eight 3-week trea...

Multiple myeloma is a monoclonal malignant proliferation of plasma cells. The disease is more frequent in men, and the average age of patients at the time of diagnosis of the disease is about 60 years. Solitary myeloma may be the first manifestation of the disseminated form of multiple myeloma, which is characterized by multiple skeletal lesions, general metabolic alterations, impairment of ren...

Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse...

Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II tria...

multiple myeloma (mm), is the second most common blood cancer after non-hodgkin’s lymphoma. genetic changes, structural and numerical chromosome anomalies, are involved in pathogenesis of mm, and are among the most important prognostic factors of disease-associated patient survival. micrornas (mirnas) are small 19-22 nucleotide single-stranded rnas involved in important cellular processes. cyto...